Neuroplasticity Biomarkers in Aphasia

Recruiting now · Not applicable

Conditions studied: Aphasia, Language, Stroke

In brief

Patients with stroke frequently suffer from aphasia, a disorder of expressive and/or receptive language, that can lead to serious health consequences, including social isolation, depression, reduced quality of life, and increased caregiver burden. Aphasia recovery varies greatly between individuals, and likely relies upon the capacity for neuroplasticity, both at a systems level of reorganized brain networks and a molecular level of neuronal repair and plasticity. The proposed work will evaluate genetic and neural network biological markers of neuroplasticity associated with variability in aphasia, with a future goal to improve prognostics and identify therapeutic targets to reduce the long-term burdens of aphasia.

Key facts

Study ID

NCT06471127

Run by

University of Wisconsin, Madison

People needed

90

Starts

2025-03-17

Expected to finish

2029-05-31

Last updated by the study team

2026-07-07

Who can join

Age: 40 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ages 40-90
• Right-handed (prior to stroke)
• Proficient English speakers
• History of a single ischemic stroke in the middle cerebral artery territory that is lateralized to the left or right (Aim 1) cerebral hemisphere.
• Presence of aphasia (Aims 2-3)
• Capacity to understand the nature of the study and provide informed consent
• Acute or subacute stroke at the time of Aim 1 enrollment; Stroke #12 months old (chronic) at the time of Aims 2-3 enrollment
• Medically stable

You may not qualify if…

• History of significant medical or neurological disorder (other than stroke)
• History of significant or poorly controlled psychiatric disorders
• Current abuse of alcohol or drugs, prescription or otherwise
• Clinically significant and uncorrected vision or hearing loss
• Anything other than standard of care stroke treatment such as Plavix, aspirin (81-300 mg daily), beta-blockers, diabetes medications or choles- terol-lowering agents, thrombolytics (e.g., tPA), anticoagulation agents such as Heparin, Warfarin/Coumadin

Where it is running

• UW School of Medicine and Public Health — Madison, Wisconsin, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.